From left: Myosana CEO Matthew Lumley, with co-founders Stanley Froehner and Nick Whitehead. (Myosana and UW Photos) The news: Myosana Therapeutics, a Seattle startup developing gene therapy ...
"The most apparent take-away from the study findings is that a model of developmental therapy focusing on frequency, intensity, and variability of activity, exercise, and self-driven exploration may ...
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Fritz Frohse (1871-1916), a physician ...
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Deflazacort oral suspension (USRLD: Emflaza Oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback